The earnings call highlighted strong revenue growth, operational efficiency, and significant advancements in development services and pipeline progress. However, these positive aspects were balanced by challenges in sales force reconfiguration and primary care market expansion, leading to a downward adjustment in revenue guidance.

Company Guidance -

Q3 2025

In the first quarter of 2025, Biodesix reported a 21% year-over-year increase in total revenue to $18 million, driven by a 16% growth in test volumes and an 18% rise in lung diagnostic revenue. The company's gross margins improved by 80 basis points to 79.4%, and SG&A expenses decreased year-over-year. Despite a reduction in sales reps from 71 to 65 due to a reconfiguration into a territory-based sales approach, average sales rep productivity remained strong at an annualized $1 million per rep. Biodesix revised its annual revenue guidance to $80 million to $85 million, aiming for adjusted EBITDA positivity by the fourth quarter. The company's Development Services revenue grew 61% to $1.7 million, with a pipeline of $10.9 million under contract yet to be recognized.

Revenue Growth

Biodesix reported a 21% year-over-year revenue growth for Q1 2025, with total revenue reaching $18 million. Lung diagnostic revenue grew by 18%, marking the 16th consecutive quarter of over 15% growth.

Operational Efficiency

Gross margins improved by 80 basis points to 79.4%, showing enhanced operational effectiveness and cost containment, even with a modest increase in R&D spending.

Development Services Expansion

Development services revenue increased by 61% in Q1 2025 compared to Q1 2024, with $10.9 million under contract but not yet recognized, representing a 21% increase over the previous year.

Digital Ordering Success

Digital test ordering increased by 58% over the last year, with customer retention 40% higher among those utilizing digital ordering.

Pipeline Progress

Advancements in pipeline products, including the development of a new combination MRD test and expanded indications for VeriStrat, were highlighted, with plans to offer the MRD test to biopharma by the end of 2025.

Biodesix (BDSX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BDSX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 31, 2025	2025 (Q3)	-0.07 / -	-0.07	―	―	―
Aug 07, 2025	2025 (Q2)	-0.07 / -0.08	-0.08	0.00% (0.00)	―
May 13, 2025	2025 (Q1)	-0.07 / -0.08	-0.14	42.86% (+0.06)	―
Mar 03, 2025	2024 (Q4)	-0.07 / -0.06	-0.1	40.00% (+0.04)	―
Nov 01, 2024	2024 (Q3)	-0.07 / -0.07	-0.14	50.00% (+0.07)	―
Aug 07, 2024	2024 (Q2)	-0.09 / -0.08	-0.17	52.94% (+0.09)	―
May 08, 2024	2024 (Q1)	-0.14 / -0.14	-0.24	41.67% (+0.10)	―
Mar 01, 2024	2023 (Q4)	-0.11 / -0.10	-0.35	71.43% (+0.25)	―
Nov 07, 2023	2023 (Q3)	-0.15 / -0.14	-0.34	58.82% (+0.20)	―
Aug 07, 2023	2023 (Q2)	-0.21 / -0.17	-0.4	57.50% (+0.23)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BDSX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.45	$0.40	-11.11%
May 13, 2025	$0.36	$0.22	-38.89%
Mar 03, 2025	$0.71	$0.72	+1.41%
Nov 01, 2024	$1.70	$1.30	-23.53%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biodesix (BDSX) report earnings?

Biodesix (BDSX) is schdueled to report earning on Oct 31, 2025, After Close (Confirmed).

What is Biodesix (BDSX) earnings time?

Biodesix (BDSX) earnings time is at Oct 31, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BDSX EPS forecast?

BDSX EPS forecast for the fiscal quarter 2025 (Q3) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing